Whitehawk Therapeutics
WHWK· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -23.3% in FY2025
David Lennon is the CEO of Whitehawk Therapeutics and was paid $3.4M in FY2025 (Dec), up 232%.
Pay$100 in the stock at the end of FY22 → $19
Executives3
See all- 1David LennonPresident and Chief Executive OfficerFY2025
- 2Scott GiacobelloChief Financial OfficerFY2025
- 3Bryan BallChief Technical Operations OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allWhitehawk Therapeutics paid its 3 named executives $7.3M in total in FY2025 (Dec). CEO David Lennon was paid $3.4M of that.
| Name | |||
|---|---|---|---|
| David LennonPresident and Chief Executive Officer | |||
| Scott GiacobelloChief Financial Officer | |||
| Bryan BallChief Technical Operations Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Whitehawk Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Emma ReeveDirector · 4 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Neil Desai, Ph.D.Director · 4 yr on the boardNot independent—Paid as an executive
- Richard MarounDirector · 4 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Mohammad Hirmand, M.D.Director · 2 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 13, 2024 | FY2023 |
